What are the consequences of sudden discontinuation of tazetostat after taking it for six months?

If patients suddenly discontinue treatment with tazemetostat after approximately six months of treatment, disease control may be adversely affected. , because tazerestat delays the proliferation of tumor cells by targeting the activity of EZH2 enzyme in the treatment of follicular lymphoma (FL; non-Hodgkin lymphoma) and other cancers. Once the drug is discontinued, the drug's inhibitory effect on tumors will disappear, and tumor cells may quickly become active again, leading to cancer recurrence or worsening of the condition.

Often, abrupt discontinuation of a drug can lead to a rapid relapse of the disease, especially in patients whose tumors have been effectively controlled by the drug. Cancer cells usually experience a certain degree of suppression under the influence of drugs, but sudden discontinuation of drugs may reactivate tumor cells and even lead to cancer progression.

For some patients who rely on tazerestat to control their condition, tumors may proliferate faster after the drug is suddenly stopped, leading to rapid disease progression. Therefore, if the patient decides to stop taking the drug due to side effects or other reasons, it is recommended to gradually reduce the dose under the guidance of a doctor rather than stopping the drug immediately. The doctor will develop an appropriate medication reduction plan based on the patient's specific conditions to minimize the adverse effects of discontinuing medication.

For those patients whose disease is in complete remission or in a stable phase, doctors may consider discontinuing the medication based on changes in their condition and the patient's overall health. However, even such patients should discontinue the drug under close supervision by a physician. Especially in long-term targeted therapy, any discontinuation may lead to cancer cell recurrence, so monitoring and adjustment are crucial.

In addition, after stopping the drug, some patients may enter the drug resistance period, when the tumor's response to the drug becomes weaker and the treatment effect is significantly reduced. If the condition worsens after stopping the drug, the patient may need to be restarted with other drugs or other treatments.

Reference materials:https://www.tazverik.com/